Institut de Neurociències (INc) - UAB Barcelona

The Scientific Genius of Caty Casas. In Memoriam

The Scientific Genius of Caty Casas. In Memoriam

2020 has been hard. Sadly, last June, Dr. Caty Casas left us and, before the year comes to an end, we would like to dedicate to her some words of remembrance. Thanks to Drs. Esther Dalfó, Elena Galea, Lydia Giménez-Llort, Julia Lorenzo, Josefa Sabrià and Montserrat Solanas for writing this beautiful text on behalf of the Institute. We feel lucky for having had the chance to work with Caty. In memoriam.


Caty Casas, a neurobiologist with an inordinate commitment to helping patients with difficult neurological ailments, passed away in June 2020, leaving extraordinary lessons of friendship, mentorship, and originality in scientific discovery.

Caty was a world-renowned expert in autophagy, the mechanism whereby cells get rid of junk materials. Autophagy is at the center stage of CNS therapeutics because neurons degenerate in chronic diseases and aging, and do not properly regenerate after acute injuries, in part because they are clogged with clutter. However, the obvious solution of treating CNS diseases by stimulating autophagy has failed in numerous clinical trials. A point in case is the broad autophagy activator rapamycin, enthusiastically embraced as a miracle drug, to no avail. Caty understood that the failure of a drug means incomplete knowledge of the underlying biology. So, with characteristic determination and talent, her team advanced autophagy-targeting therapeutics by developing better models of autophagic dysfunction.

First, they unraveled networks of signaling pathways involved in autophagy using proteomics data from animal models of traumatic peripheral nerve injury. Second, they resorted to artificial intelligence to gain insight into how these networks could be manipulated for therapeutic purposes. They thus pioneered the vision that big data and computerized tools are most valuable tools to cure complex diseases. Third, they created a highly inventive approach to modulating autophagy: simultaneous activation of two pathways with opposite actions on the autophagic flux. The details can be found in their last article(1).

The key idea is that therapies should restore the complex web of homeostatic feedbacks that regulate autophagy in neurons and is damaged by injury. They explain their strategy with the beautiful analogy that autophagy is to neurons what a shield is to a warrior: ‘A warrior wearing a shield is almost unbeatable. But any damage to the shield would reduce the possibilities of the warrior to avoid accurate blows. Then it is reasonable to think that the repair of the shield will enhance the chances of survival of the warrior. This was the rationale behind our discovery of NeuroHeal(2). There are endogenous mechanisms of protection that neurons (and other cells) immediately engage in upon insult or damage. The fact that neurons are long-lived cells is indeed in agreement with the presence of potent endogenous mechanisms of neuroprotection that include the unfolded protein response (UPR), the ubiquitin proteasome system (UPS), anti-apoptotic mechanisms, antioxidant reactions and autophagy, to cite a few. There is, however, a wealth of evidence supporting malfunction of some or several of these processes during aging and neurodegeneration –holes in the warrior’s shield’ (1).

While fighting a fatal disease like a warrior herself, Caty paved the way for novel avenues that challenged dogma and stagnation in drug discovery and CNS therapeutics. An idealist seeking justice and freedom in all realms of life, she was uniquely generous, honest, and compassionate. Her passion to build, learn and do good was contagious, as was her unforgettable laughter. We will always celebrate the gift of the luminous presence of Caty Casas in our lives.

Read Patricia Boya's article in Autophagy on Caty's work

Read Caty's interview on the INc-UAB blog


(1) David Romeo-Guitart, Sara Marmolejo-Martínez-Artesero & Caty Casas (2020): Is it the time of autophagy fine-tuners for neuroprotection? Autophagy, Jul 17;1


Related news

The H2020 project QSPainRelief awarded by the European Commission

The H2020 project QSPainRelief awarded by the European Commission

The QSPainRelief project "Effective combinational treatment of chronic pain in individual patients by an innovative quantitative systems pharmacology pain relief approach", which includes the participation of Dr. Jesús Giraldo’s team (Institute for Neurosciences and Biostatistics Unit of the School of Medicine), has been funded from the European Commission.

This  project will attempt to solve a crucial problem since about 20% of Europeans suffer from chronic pain and current therapies are not effective in many cases. Around 60% of patients do not reach enough relief from traditional painkillers, which in turn can lead to several adverse effects.

The QSPainRelief project addresses the problem of chronic pain by identifying new drug combinations that are expected to increase analgesic efficacy while reducing side effects. To do this, quantitative systems pharmacology and computational modeling will be used. The best combinations will be validated in animal models and clinical studies.

The QSPainRelief project will receive more than € 6 million in funding for 5 years through the H2020 program. The project is a collaboration between 9 research institutions from 6 different countries, including the UAB, starting January 1, 2020.

A new model of the worm C. elegans to progress in the study of a rare disease of the nervous system

A new model of the worm C. elegans to progress in the study of a rare disease of the nervous system

In a research co-directed by Dr Esther Dalfó, researcher at the Institute and professor at UVic-UCC, a model of chromosome X-linked adrenoleukodystrophy (x-ALD) has been indentified in the earthworm C. elegans.

The model will permit to accelerate and reduce the price of the research, which is studying the mechanisms and the possible pharmacological targets for the neuronal alterations of this disease.

The earliest results of studies with this organism point to glial cells as a man responsible for the neurological damage caused by the disease.

The work was done at the IDIBELL Neurometabolic Diseases group, with international collaborations, and has been published in the Free Radical Biology and Medicine journal.

Read the article

View all news